Sugi Predict

Sugi Predict / Compounds / SCHEMBL210293

SCHEMBL210293

SCHEMBL210293

O=Cc1c(Cl)cc(OCc2ccccc2)cc1Cl

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 1/20 0.55
▸ MAOB P27338 1/20 0.55
▸ MEN1 O00255 3/20 0.50
▸ KMT2A Q03164 3/20 0.50
▸ NPC1 O15118 3/20 0.49
▸ RAB9A P51151 3/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ MAPT P10636 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ CCNB2 O95067 1/20 0.47
▸ CDK1 P06493 1/20 0.47
▸ CDK4 P11802 1/20 0.47
▸ CCNB1 P14635 1/20 0.47
▸ CCND1 P24385 1/20 0.47
▸ CCNB3 Q8WWL7 1/20 0.47
▸ ALOX5 P09917 1/20 0.46
▸ HPGD P15428 1/20 0.45
▸ BCHE P06276 2/20 0.45
▸ GSTP1 P09211 1/20 0.45
▸ CA12 O43570 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1842456 0.91 NPC1 (0.50) MAOAMAOBMEN1KMT2ANPC1
SCHEMBL1250536 0.83 NPC1 (0.57) MAOBMEN1KMT2ANPC1RAB9A
SCHEMBL190184 0.81 HPGD (0.58) MAOAMAOBMEN1KMT2ANPC1
SCHEMBL3196407 0.80 ALOX5 (0.53) MAOAMAOBMEN1KMT2ANPC1
SCHEMBL856074 0.80 MAOA (0.55) MAOAMAOBMEN1KMT2ANPC1
SCHEMBL515204 0.80 NPC1 (0.56) MAOAMAOBMEN1KMT2ANPC1
SCHEMBL10735179 0.80 NPC1 (0.51) MAOAMAOBMEN1KMT2ANPC1
SCHEMBL31725679 0.79 APP (0.53) MAOAMAOBMEN1KMT2ANPC1
SCHEMBL955846 0.79 MAOB (0.54) MAOAMAOBMEN1KMT2ANPC1
SCHEMBL24089571 0.78 SMN1; SMN2 (0.60) MAOANPC1RAB9ASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12466781-B2 Thyromimetics AUTOBAHN THERAPEUTICS, INC. (US) 2025-11-11 — — US disclosed
US-12006294-B2 Therapeutic compounds REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2024-06-11 — — US disclosed
US-20230242471-A1 THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2023-08-03 — — US disclosed
US-20230242471-A1 THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2023-08-03 — — US disclosed
US-20230048992-A1 NOVEL THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2023-02-16 — — US disclosed
US-20230048992-A1 NOVEL THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2023-02-16 — — US disclosed
CN-115279359-A Novel thyromimetic agents 速通医疗公司 2022-11-01 — — CN disclosed
EP-4065098-A1 NOVEL THYROMIMETICS Autobahn Therapeutics, Inc. (US) 2022-10-05 — — EP disclosed
WO-2021257851-A1 THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. (US) 2021-12-23 — — WO disclosed
WO-2021108549-A1 NOVEL THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. (US) 2021-06-03 — — WO disclosed
WO-2007124254-A2 CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2007-11-01 — — WO disclosed
WO-2007124329-A1 CYCLOHEXYLIMIDAZOLE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2007-11-01 — — WO disclosed
EP-1807072-A1 CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2007-07-18 — — EP disclosed
WO-2007026024-A2 BENZODIAZEPINES AS HCV INHIBITORS TIBOTEC PHARMACEUTICALS LTD. (IE) 2007-03-08 — — WO disclosed
WO-2006128056-A2 NOVEL PHOSPHINIC ACID-CONTAINING THYROMIMETICS METABASIS THERAPEUTICS, INC. (US) 2006-11-30 — — WO disclosed
WO-2006128055-A2 NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS METABASIS THERAPEUTICS, INC. (US) 2006-11-30 — — WO disclosed
EP-1689383-A2 NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS Metabasis Therapeutics, Inc. (US) 2006-08-16 — — EP disclosed
WO-2006049952-A1 CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2006-05-11 — — WO disclosed
US-20060046980-A1 Novel phosphorus-containing thyromimetics METABASIS THERAPEUTICS, INC. 2006-03-02 — — US disclosed
WO-2005051298-A2 NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS METABASIS THERAPEUTICS, INC. (US) 2005-06-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230048992-A1 NOVEL THYROMIMETICS TSHR, TPO, CHRM1 MAOA 596/4885MAOB 653/4885MEN1 170/4885
US-12466781-B2 Thyromimetics TPO, TSHR, CHRM1 MAOA 592/4885MAOB 574/4885MEN1 138/4885
US-20060046980-A1 Novel phosphorus-containing thyromimetics PYGL, THRA, THOP1 MAOA 3717/4885MAOB 3749/4885MEN1 1845/4885
US-12006294-B2 Therapeutic compounds OPRL1, INA, OGFR MAOA 1676/4885MAOB 1217/4885MEN1 4058/4885
US-20230242471-A1 THYROMIMETICS TPO, THOP1, THRB MAOA 470/4885MAOB 488/4885MEN1 708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.